Betydning af vascular endothelial growth factor;- VEGF - ved tumorangiogenese: Terapeutiske muligheder ved solide tumorer

Ugeskrift for Laeger

Volumn 162, Issue 37, 2000, Pages 4916-4920

  Werther, Kim ^a   Nielsen, Hans Jørgen ^a  

^a HVIDOVRE HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; VASCULOTROPIN; VASCULOTROPIN A;

ARTICLE; CHEMISTRY; DRUG EFFECT; GENETICS; HUMAN; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; HUMANS; LYMPHOKINES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034637759     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. McNamara DA, Harmey JH, Walsh TN, Redmond HP, Bouchier-Hayes DJ. Significance of angiogenesis in cancer therapy. Br J Surg 1998; 85: 1044-55.
2. Cuthbert MF, Asscher AW, Jones JH. Characterization of a vascular permeability factor of renal origin. Clin Sci 1966; 31: 325-36.
3. Hayashi H, Kinuwaki Y, Yoshinaga M. Inhibition of anaphylactic release of vascular permeability factor or histamine by specific protease inhibitor in tissue culture. Nature 1965; 208: 1007-8.
4. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161: 851-8.
5. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-9.
6. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435-9.
7. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996; 380: 439-42.
8. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-6.
9. Senger DR, Van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 1993; 12: 303-24.
10. Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992; 3: 211-20.
11. Freeman MR, Schneck FX, Gagnon ML, Corless C, Soker S, Niknejad K et al. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 1995; 55: 4140-5.
12. Iijima K, Yoshikawa N, Connolly DT, Nakamura H. Human mesangial cells and peripheral blood mononuclear cells produce vascular permeability factor. Kidney Int 1993; 44: 959-66.
13. Wartiovaara U, Salven P, Mikkola H, Lassila R, Kaukonen J, Joukov V et al. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost 1998; 80: 171-5.
14. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993; 4: 1317-26.
15. Salven P, Lymboussaki A, Heikkila P, Jaaskela-Saari H, Enholm B, Aase K et al. Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors. Am J Pathol 1998; 153: 103-8.
16. Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A 1998; 95: 548-53.
17. Minet E, Michel G, Remacle J, Michiels C. Role of HIF-1 as a transcription factor involved in embryonic development, cancer progression and apoptosis. Int J Mol Med 2000; 5: 253-9.
18. Faller DV. Endothelial cell responses to hypoxic stress. Clin Exp Pharmacol Physiol 1999; 26: 74-84.
19. Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol 1999; 9: 211-20.
20. Ono T, Miki C. Factors influencing tissue concentration of vascular endothelial growth factor in colorectal carcinoma. Am J Gastroenterol 2000; 95: 1062-7.
21. Vermeulen PB, Van den Eynden GG, Huget P, Goovaerts G, Weyler J, Lardon F et al. Prospective study of intratumoral microvessel density, p53 expression and survival in colorectal cancer. Br J Cancer 1999; 79: 316-22.
22. Salven P, Manpaa H, Orpana A, Alitalo K, Joensuu H. Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res 1997; 3: 647-51.
23. Werther K, Christensen IJ, Brünner NA, Nielsen HJ. Soluble VEGF levels in patients with primary colorectal carcinoma. Eur J Surg Oncol 2000 (i trykken).
24. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-4.
25. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 1995; 95: 1789-97.
26. Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000; 95: 2637-44.
27. Salven P, Orpana A, Joensuu H. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 1999; 5: 487-91.
28. Maniwa Y, Okada M, Ishii N, Kiyooka K. Vascular endothelial growth factor increased by pulmonary surgery accelerates the growth of micrometastases in metastatic lung cancer. Chest 1998; 114: 1668-75.
29. Gabrilorich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92: 4150-66.
30. Nielsen HJ, Werther K, Mynster T, Brünner NA. Soluble vascular endothelial growth factor in various blood transfusion components. Transfusion 1999; 39: 1078-83.
31. Nielsen HJ. Clinical impact of bioactive substances in blood components: implications for leukocyte filtration. Infusionsther Transfusionsmed 1998; 25: 296-304.